Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5112013 | 0.86 | PTGS2 (0.84) | PTGS2 | |
| SCHEMBL18517392 | 0.86 | PTGS2 (0.72) | PTGS2 | |
| SCHEMBL13286980 | 0.85 | PTGS2 (0.93) | PTGS2 | |
| SCHEMBL22504102 | 0.84 | PTGS2 (0.98) | PTGS2 | |
| SCHEMBL8360236 | 0.84 | PTGS2 (0.76) | PTGS2 | |
| SCHEMBL18517535 | 0.84 | PTGS2 (0.59) | PTGS2 | |
| SCHEMBL2011840 | 0.84 | PTGS2 (0.71) | PTGS2 | |
| SCHEMBL14346030 | 0.83 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL6398477 | 0.83 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL2007429 | 0.83 | PTGS2 (0.72) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752582-B2 | Augmenting moieties for anti-inflammatory compounds | LEHIGH UNIVERSITY (US) | 2020-08-25 | — | — | US | disclosed |
| US-20170044096-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | LEHIGH UNIVERSITY | 2017-02-16 | — | — | US | disclosed |
| US-9512068-B2 | Augmenting moieties for anti-inflammatory compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160031804-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | LEHIGH UNIVERSITY | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752582-B2 | Augmenting moieties for anti-inflammatory compounds | PTGES, PTGES3, LRBA | PTGS2 29/4885 |
| US-20160031804-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | PTGES, ICAM1, VCAM1 | PTGS2 12/4885 |
| US-20170044096-A1 | Augmenting Moieties for Anti-Inflammatory Compounds | PTGES, PTGES3, LRBA | PTGS2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.